Dasiglucagon is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above. It is available as injection for subcutaneous use. MedsAcross supplies Dasiglucagon for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ZEGALOGUE ® is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above. ZEGALOGUE is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Source: US FDA prescribing information
Dasiglucagon is a glucagon receptor agonist, which increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for dasiglucagon to produce an antihypoglycemic effect.
Source: US FDA prescribing information
• ZEGALOGUE autoinjector and prefilled syringe are for subcutaneous injection only. • The dose in adults and pediatric patients aged 6 years and older is 0.6 mg. • Administer ZEGALOGUE according to the printed instructions on the protective case label and the Instructions For Use. • Visually inspect ZEGALOGUE prior to administration. The solution should appear clear, colorless, and free from particles. If the solution is discolored or contains particulate matter, do not use. • Administer the injection into the lower abdomen, buttocks, thigh, or outer upper arm. • Call for emergency assistance immediately after administering the dose. • If there has been no response after 15 minutes, an additional dose of ZEGALOGUE from a new device may be administered while waiting for emergency assistance. • When the patient has responded to treatment, give oral carbohydrates.
Source: US FDA prescribing information
ZEGALOGUE is contraindicated in patients with: • Pheochromocytoma because of the risk of substantial increase in blood pressure • Insulinoma because of the risk of hypoglycemia Pheochromocytoma. Insulinoma
Source: US FDA prescribing information
• Substantial Increase in Blood Pressure in Patients with Pheochromocytoma: Contraindicated in patients with pheochromocytoma because ZEGALOGUE may stimulate the release of catecholamines from the tumor. • Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose, but ZEGALOGUE may stimulate exaggerated insulin release from an insulinoma and cause subsequent hypoglycemia. If a patient develops symptoms of hypoglycemia after a dose of ZEGALOGUE, give glucose orally or intravenously. • Hypersensitivity and Allergic Reactions: Allergic reactions have been reported with glucagon products and may include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension.
Source: US FDA prescribing information
The following important adverse reactions are described elsewhere in the labeling: • Hypersensitivity and Allergic Reactions Most common adverse reactions (≥2%) associated with ZEGALOGUE are: Adults: nausea, vomiting, headache, diarrhea, and injection site pain Pediatrics: nausea, vomiting, headache, and injection site pain
Source: US FDA prescribing information
Table 3. Clinically Significant Drug Interactions with ZEGALOGUE Beta-Blockers Clinical Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given ZEGALOGUE. Indomethacin Clinical Impact: In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may even produce hypoglycemia. Warfarin Clinical Impact: ZEGALOGUE may increase the anticoagulant effect of warfarin. • Beta-blockers: Patients taking beta-blockers may have a transient increase in pulse and blood pressure. • Indomethacin: In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may produce hypoglycemia. • Warfarin: ZEGALOGUE may increase the anticoagulant effect of warfarin.
Source: US FDA prescribing information
Storage Store ZEGALOGUE in a refrigerator, 2°C to 8°C (36°F to 46°F). Do not freeze. ZEGALOGUE can be kept at room temperature between 20°C to 25°C (68°F to 77°F) for up to 12 months. Record the date when the product was removed from the refrigerator in the space provided on the protective case. Do not return the product to the refrigerator after storing at room temperature. Discard ZEGALOGUE after the end of the 12-month period at room temperature storage, or after the expiration date stated on the product, whichever occurs first. Store in the provided protective case and protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Dasiglucagon, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Zegalogue 0.6 mg/0.6 mL injectionSubcutaneous Cold chain | Novo Nordisk | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Dasiglucagon and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Dasiglucagon, including Zegalogue.
Yes. The US FDA first approved Dasiglucagon on 22 March 2021, according to Drugs@FDA.
Yes. Dasiglucagon has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Dasiglucagon must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Dasiglucagon is classified under ATC code H04AA02 (Dasiglucagon).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.